<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861094</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000595050</org_study_id>
    <secondary_id>FRE-FNCLCC- ACCORD-17-0707</secondary_id>
    <secondary_id>EU-20848</secondary_id>
    <nct_id>NCT00861094</nct_id>
  </id_info>
  <brief_title>Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer</brief_title>
  <official_title>Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Oesophageal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) together with radiation&#xD;
      therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II/III trial is studying radiation therapy and two different&#xD;
      combination chemotherapy regimens to compare how well they work as first-line therapy in&#xD;
      treating patients with esophageal cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the feasibility of radiochemotherapy comprising oxaliplatin, fluorouracil, and&#xD;
           leucovorin calcium (FOLFOX regimen) vs fluorouracil and cisplatin (Herskovic regimen) in&#xD;
           patients with inoperable esophageal cancer. (Phase II)&#xD;
&#xD;
        -  To assess the endoscopic complete response rate in patients treated with these regimens.&#xD;
           (Phase II)&#xD;
&#xD;
        -  To compare the event-free survival of patients treated with these regimens. (Phase III)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the toxicity profile of these regimens using the NCI CTC v2.0 criteria. (Phase&#xD;
           II)&#xD;
&#xD;
        -  To compare the overall survival, endoscopic complete response rate, incidence of grade&#xD;
           3-4 toxicities, and time to treatment failure in patients treated with these regimens.&#xD;
           (Phase III)&#xD;
&#xD;
        -  To evaluate the quality of life of these patients using EORTC QLQ-C30 (version 3) and a&#xD;
           validated disease-specific module EORTC QLQ-OES18. (Phase III)&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to histological type&#xD;
      (adenocarcinoma or adenosquamous carcinoma vs squamous cell carcinoma), pretreatment weight&#xD;
      loss within the past 6 months (grade 1 [&lt; 10%] vs grade 2 [â‰¥ 10%]), ECOG performance status&#xD;
      (0 vs 1 vs 2), and participating center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (modified FOLFOX 4 regimen): Patients undergo radiotherapy 5 days a week for 5&#xD;
           weeks. Beginning concurrently with radiotherapy, patients receive oxaliplatin IV over 2&#xD;
           hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously&#xD;
           over 46 hours on days 1 and 2. Treatment with chemotherapy repeats every 2 weeks for up&#xD;
           to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II (Herskovic regimen): Patients undergo radiotherapy as in arm I. Patients also&#xD;
           receive cisplatin IV continuously over 24 hours on day 1 and fluorouracil IV&#xD;
           continuously over 96 hours on days 1-4 of weeks 1, 5, 8, and 11 in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, periodically during study therapy, and then every 6&#xD;
      months for 1 year and annually for 3 years after completion of study therapy.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 4 weeks and then every 3-6 months&#xD;
      until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 97 patients will be accrued for the phase II portion of the&#xD;
      study. A total of 169 patients will be accrued for the phase III portion of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who complete the full study treatment (Phase II)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endoscopic complete response rate (Phase II)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (Phase III)</measure>
    <time_frame>Until progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile as assessed by NCI CTC v2.0 (Phase II)</measure>
    <time_frame>Total duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Phase III)</measure>
    <time_frame>Total duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (Phase III)</measure>
    <time_frame>Total duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (Phase III)</measure>
    <time_frame>Total duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3-4 toxicities (Phase III)</measure>
    <time_frame>Total duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by EORTC QLQ-C30 (version 3) and EORTC QLQ-OES18 (Phase III)</measure>
    <time_frame>Total duration of the trial</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX and radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin (85mg/m2); Folinic Acid (200mg/m2); 5-FU (400mg/m2-Bolus and 1600mg/m2 over 46h)- once every two weeks for six cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-FU / cisplatin and radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-FU (100mg/m2); Cisplatin (75mg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>5-FU / cisplatin and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <arm_group_label>5-FU / cisplatin and radiotherapy</arm_group_label>
    <arm_group_label>FOLFOX and radiotherapy</arm_group_label>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <arm_group_label>FOLFOX and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>5-FU / cisplatin and radiotherapy</arm_group_label>
    <arm_group_label>FOLFOX and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <arm_group_label>FOLFOX and radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven adenocarcinoma, squamous cell carcinoma, or adenosquamous&#xD;
             carcinoma of the esophagus&#xD;
&#xD;
               -  Locally advanced disease (any T, N0 or N1, M0 or M1a)&#xD;
&#xD;
                    -  No metastatic disease, except for tumor involvement of the upper third of&#xD;
                       the esophagus or cervical esophageal tumor with regional nodes, or tumor&#xD;
                       involvement of the lower third of the esophagus with celiac nodes (M1a)&#xD;
&#xD;
                         -  Cervical primary tumor with positive supraclavicular or cervical lymph&#xD;
                            nodes (defined as N1) allowed&#xD;
&#xD;
                         -  No radiographic evidence of enlarged (â‰¥ 1.5 cm) celiac lymph nodes by&#xD;
                            CT scan or echography&#xD;
&#xD;
               -  No small cell or undifferentiated carcinoma of the esophagus&#xD;
&#xD;
               -  No multiple carcinomas of the esophagus (i.e., &gt; 1 esophageal tumor)&#xD;
&#xD;
               -  No cardia tumor (Siewert II) or gastric tumor extension to the esophagus (Siewert&#xD;
                  III)&#xD;
&#xD;
                    -  Esophageal tumor extension to the cardia (Siewert I) (center of the tumor&#xD;
                       lying &gt; 1 cm-5 cm above gastroesophageal junction) allowed&#xD;
&#xD;
          -  Inoperable disease OR surgery is contraindicated&#xD;
&#xD;
          -  No tracheo-esophageal fistula or invasion of the tracheo-bronchial tree&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy â‰¥ 3 months&#xD;
&#xD;
          -  Absolute neutrophil count â‰¥ 1,500/mmÂ³&#xD;
&#xD;
          -  Platelet count â‰¥ 100,000/mmÂ³&#xD;
&#xD;
          -  Hemoglobin â‰¥ 10 g/dL (transfusion allowed)&#xD;
&#xD;
          -  Creatinine &lt; 15 mg/L&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST &lt; 2.5 times ULN&#xD;
&#xD;
          -  Prothrombin time â‰¥ 60%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Caloric intake sufficient (i.e., &gt; 1,000 Kcal/mÂ²/day) (orally or with gastrostomy)&#xD;
&#xD;
          -  No weight loss &gt; 20% normal body weight within the past 3 months&#xD;
&#xD;
          -  No complete dysphagia&#xD;
&#xD;
          -  No exclusive requirement for parenteral nutrition&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
               -  No sensitive peripheral neuropathy with functional impairment&#xD;
&#xD;
          -  No auditory disorders&#xD;
&#xD;
          -  No other prior malignancies except curatively treated nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix or stage I or II node-negative head and neck cancer&#xD;
             that was curatively treated &gt; 3 years ago&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Patients who have had a myocardial infarction &gt; 6 months ago are eligible&#xD;
                  provided there is no transient ischemia by thallium myocardial scintigraphy and&#xD;
                  patient is able to undergo chemotherapy , as determined by a cardiologist&#xD;
&#xD;
          -  No other serious illness or medical condition (e.g., symptomatic coronary disease,&#xD;
             left ventricular failure, or uncontrolled infection)&#xD;
&#xD;
          -  No stage II-IV arterial disease, according to the DE LERICHE and FONTAINE&#xD;
             classification&#xD;
&#xD;
          -  No geographical, social, or psychological circumstances preventing regular follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior treatment for esophageal cancer (e.g., surgery, chemotherapy, or&#xD;
             radiotherapy)&#xD;
&#xD;
          -  No prior cervical, thoracic, or abdominal radiotherapy with field overlapping the&#xD;
             proposed esophageal radiotherapy field&#xD;
&#xD;
          -  More than 30 days since prior experimental drugs or participation in another clinical&#xD;
             trial&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent phenytoin or yellow fever vaccine&#xD;
&#xD;
          -  No concurrent high-dose, long-term corticosteroids&#xD;
&#xD;
          -  No concurrent calcium gluconate/magnesium sulfate infusions&#xD;
&#xD;
          -  No concurrent hematopoietic growth factors&#xD;
&#xD;
          -  No concurrent esophageal dilatation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Conroy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Alexis Vautrin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHR de Besancon - Hopital Saint-Jacques</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Ambroise Pare</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>F-92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Du Parc</name>
      <address>
        <city>Caen</city>
        <zip>14052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Regional Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Robert Debre</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine De Radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>F-22015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Du Parc</name>
      <address>
        <city>Toulouse</city>
        <zip>31078</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>stage IIA esophageal cancer</keyword>
  <keyword>stage IIB esophageal cancer</keyword>
  <keyword>stage IIIA esophageal cancer</keyword>
  <keyword>stage IIIB esophageal cancer</keyword>
  <keyword>stage IIIC esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

